GLUE
Monte Rosa Therapeutics Inc
10.30$
-2.2%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 72.6% | 77.8% | 74.6% | 80.8% | 79.7% | 86.0% | 84.5% | 83.3% | 87.4% | 87.6% | 92.0% | 91.4% | |
| 23.4% | 42.2% | 37.4% | 31.6% | 39.9% | 51.1% | 20.0% | 19.3% | 45.3% | 28.9% | 21.7% | 12.9% | |
| 70.8% | 76.5% | 72.3% | 76.2% | 76.9% | 84.8% | 82.9% | 80.8% | 85.1% | 84.1% | 90.5% | 89.2% | |
| 0.1% | 0.2% | 0.2% | 2.9% | 0.2% | 0.0% | 0.4% | 0.7% | 1.1% | 1.0% | 0.6% | 1.4% | |
| – | – | – | 0.0% | – | – | – | – | – | – | – | – | |
| 26.8% | 41.0% | 42.8% | 34.7% | 34.8% | 49.2% | 30.0% | 25.4% | 46.5% | 48.1% | 29.1% | 30.3% | |
| 9.0% | 15.3% | 15.5% | 12.3% | 13.2% | 35.8% | 15.1% | 11.6% | 13.4% | 14.3% | 9.6% | 9.6% | |
| 1.1% | 1.0% | 1.3% | 1.0% | 1.2% | 0.8% | 1.0% | 1.1% | 0.9% | 1.0% | 0.6% | 0.7% | |
| 2.2% | 3.7% | 2.6% | 1.9% | 1.3% | 3.9% | 1.7% | 1.6% | 3.2% | 0.8% | 1.1% | 1.0% | |
| 73.2% | 59.0% | 57.2% | 65.3% | 65.2% | 50.8% | 70.0% | 74.6% | 53.5% | 51.9% | 70.9% | 70.0% | |
| -131.9% | -120.5% | -149.2% | -124.4% | -143.5% | -100.0% | -99.6% | -112.4% | -93.7% | -106.4% | -70.8% | -81.2% | |
| 19.8% | 18.7% | 22.6% | 20.7% | 26.0% | 14.0% | 21.1% | 17.2% | 13.4% | 14.6% | 11.5% | 12.2% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.